Table 1 Characteristics of the study population at the time of the assessment (N = 223)
From: The association between sonographic enthesitis and radiographic damage in psoriatic arthritis
Variable | Value |
|---|---|
Demographics: | |
 Age (years), mean ± SD | 56 ± 12.9 |
 Male gender, n (%) | 129 (57.9) |
 PsA duration (years), mean ± SD | 16.9 ± 12.4 |
 Psoriasis skin disease duration (years), mean ± SD | 28.1 ± 14.5 |
 BMI, mean ± SD | 29.8 ± 6.1 |
 Smoking |  |
  Current, n (%) | 29 (13) |
  Past, n (%) | 70 (31.4) |
Clinical activity measures: | |
 Tender joints count, mean ± SD | 2.5 ± 5.3 |
 Swollen joint count, mean ± SD | 1.1 ± 3.3 |
 Clinical enthesitis, n (%) | 31 (13.9) |
 Dactylitis, n (%) | 9 (4) |
 PASI, mean ± SD | 2.6 ± 5.8 |
 Nail lesions, n (%) | 59 (26.4) |
HLA-B*27 | 34 (15.5) |
Radiographic evaluation: | |
 modified Steinbrocker score |  |
  mean ± SD | 18.7 ± 33.6 |
  median (25th, 75th percentile) | 4 (0, 20) |
 Arthritis mutilans, n (%) | 20 (9) |
 Joint ankylosis, n (%) | 26 (11.7) |
 Periostitis, n (%) | 49 (22.2) |
 mSASSS, |  |
  mean ± SD | 1.7 ± 7.2 |
  median (25th, 75th percentile) | 0 (0, 0) |
 Sacroiliitis, n (%), | 82 (37.1) |
Sonographic evaluation: | |
 MASEI, mean ± SD | 15.7 ± 12.6 |
Treatment: | |
 DMARDs – current use, n (%) | 102 (45.7) |
 DMARDs – ever use, n (%) | 181 (81.2) |
 Biologics – current use, n (%) | 119 (53.4) |
 Biologics – ever use, n (%) | 130 (58.3) |